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Abstract 29 
Objectives: To explore the current status of antifungal stewardship (AFS) initiatives 30 
across National Health Service (NHS) Trusts within England, the challenges and 31 
barriers as well as ways to improve current AFS programmes. 32 
Methods: An electronic survey was sent to all 155 acute NHS acute Trusts in 33 
England. 34 
Results: Forty seven Trusts, corresponding to 30% of English acute Trusts, returned 35 
a survey; 46 trusts (98%) had an antimicrobial stewardship (AMS) programme but 36 
only 5 (11%) had a dedicated AFS programme. Twenty (43%) Trusts said they 37 
included AFS as part of their AMS programmes. From those conducting AFS 38 
programmes, 7 (28%) have an AFS/management team, 16 (64%) monitor and report 39 
on antifungal usage, 5 (20%) have dedicated AFS ward rounds and 12 (48%) are 40 
directly involved in the management of invasive fungal infections. 41 
Thirteen acute Trusts (52%) started their AFS programme to manage costs, whilst 42 
12 (48%) commenced the programme due to clinical need; 27 (73%) declared that 43 
they would increase their AFS initiatives if they could. Of those without an AFS 44 
programme, 14 (67%) responded that this was due to lack of resources / staff time. 45 
Twelve Trusts (57%) responded that the availability of rapid diagnostics and clinical 46 
support would enable them to conduct AFS activities. 47 
Conclusions: Although a minority of Trusts conduct AFS programmes, nearly half 48 
include AFS as part of routine AMS activities. Cost issues are the main driver for 49 
AFS, followed by clinical need. The availability of rapid diagnostics and clinical 50 
support could help increase AFS initiatives. 51 
  52 
Introduction 53 
Antimicrobial stewardship (AMS) initiatives have until recently largely focussed on 54 
antibacterial agents. However, a number of recent studies have highlighted the 55 
importance of antifungal stewardship (AFS), outlining significant patient benefits, as 56 
well as cost-savings. (Standiford et al 2012, Lopez-Medrano 2013, Mondain et al 57 
2013, Valerio et al 2014, Micallef et al 2015) Issues addressed in AFS include 58 
selection of the most appropriate agent in terms of intrinsic antifungal activity 59 
(Parkins et al), whether additional diagnostic or biomarker tests are required, dose 60 
(especially with major organ dysfunction, drug interactions (Bartholomew et al) 61 
(which are a major issue with the azole antifungals), underlying therapy plan 62 
(increased or reduced immunosuppression, renal support etc.), addressing current or 63 
future adverse events and advising on therapeutic drug monitoring (TDM; Ashbee et 64 
al), potential for antifungal resistance and oral switch possibilities. l Resistance to 65 
antifungal agents has emerged as an area of major concern, both acquisition of 66 
intrinsically resistant fungi (Candida krusei, Candida auris (Schelenz et al), 67 
Mucorales and Fusarium spp. being good examples) and isolates with acquired 68 
resistance, notably Candida glabrata and Aspergillus fumigatus. Dual fungal infection 69 
is an increasing problem (Salehi et al). Better antifungal choices improve outcomes 70 
and reduce cost (Parkins et al; Micallef et al). Better availability and usage of non-71 
culture based fungal disease diagnostics should also reduce unnecessary anti-72 
bacterial use (Denning et al).We sought to explore the current status of AFS 73 
initiatives across National Health Service (NHS) acute Trusts within England. 74 
 75 
 76 
Methods 77 
A web-based survey containing 50 closed questions was developed and deployed by 78 
Public Health England¶s select survey programme as previously described (Ashiru-79 
Oredope et al 2015), in order to explore the status of AFS in England. There was 80 
also the opportunity to provide comments (i.e. free text). The final draft was piloted 81 
for face validity (Supplementary Information Figure S1) and disseminated to all 155 82 
NHS acute hospital trusts across England via the following networks: Lead Public 83 
Health Microbiologists (Public Health England) network, British Infection Association 84 
(BIA), UK Clinical Pharmacy Association (UKCPA) and the East of England 85 
antimicrobial pharmacist group. The survey was open for 6 weeks and reminders 86 
were issued at three weeks and again at five weeks. All NHS hospitals in England 87 
were included. NHS hospitals in Wales, Northern Ireland and Scotland and all UK 88 
private hospitals were excluded. The responses were first de-duplicated to remove 89 
multiple responses from individuals but multiple responses from the same trusts 90 
were retained if they were from different healthcare professionals (i.e. pharmacists, 91 
microbiologists etc.). Responses from non-English Trusts were also excluded from 92 
the analysis. Results were analysed using Microsoft Excel.  93 
 94 
Results 95 
In total, 47 hospital Trusts in England responded to the questionnaire, representing 96 
30% of all acute Trusts. The majority (53%; 25) were district general hospitals (small, 97 
medium and large acute Trusts), followed by teaching (36%; 17) and specialist 98 
Trusts (11%; 5)(table 1). Most respondents were microbiologists (37; 69%), followed 99 
by antimicrobial pharmacists and infectious disease physicians. A wide range of 100 
specialities was covered by participating hospitals. 101 
 102 
Only one English NHS acute Trust reported that it had no AMS programme in place 103 
(a specialist hospital). This contrasts with only five Trusts (11%) reporting having a 104 
dedicated AFS programme. Four of these were in teaching Trusts and one was in a 105 
specialist Trust. However, most Trusts had some form of informal AFS programme 106 
or monitoring ability, with 76% of Trusts having guidelines for the treatment and / or 107 
prophylaxis of invasive fungal infections. 108 
 109 
Perceived potential benefits of AFS included improvements in safety (23), outcome 110 
(19), costs (24), reduced side-effects (20) and obtaining surveillance data (18). 111 
 112 
Most hospital Trusts had access to a number of available laboratory tests (e.g. 113 
JDODFWRPDQQDQFU\SWRFRFFDODQWLJHQȕ-D-glucan; table 1). Interestingly, availability 114 
of laboratory testing was not related to the type of hospital (e.g. DGH, teaching 115 
hospital; data not shown). Of concern is the slow turnaround time reported in the 116 
questionnaire; most results were unavailable for at least 48 hours. 117 
 118 
Most AFS activities were performed by a microbiologist, followed by an antimicrobial 119 
pharmacist, infectious disease physician or other pharmacist. A variety of models 120 
were suggested. Seven Trusts reported having an AFS / management team, while 121 
five reported performing dedicated AFS ward rounds. Twelve Trusts said they 122 
offered advice on patients with invasive fungal infections. Several Trusts said they 123 
saw fungaemic patients on their general daily ward rounds. A number of respondents 124 
identified that they perform ward rounds on haematology wards and intensive care 125 
units within their hospitals. Some Trusts with no dedicated AFS programme 126 
nevertheless included patients on antifungal agents as part of their AMS work. One 127 
UHVSRQGHQWVXJJHVWHGWKH\UHYLHZHGSDWLHQWVRQDOLVWRIµUHVWULFWHGGUXJV¶DVSDUWRI128 
their AMS round, which included high-cost antifungal agents. Most suggested they 129 
performed their AFS programme weekly, but some respondents did it more 130 
frequently. Other Trusts did it as required on an ad-hoc basis. 131 
 132 
One respondent suggested they approached AFS using an analogy from infection 133 
prevention: ³WKHUH is a role for the infection prevention team but daily infection 134 
prevention activities are in everybody's job description. Our AFS team does not do 135 
specific AFS ward rounds ± we have empowered the specialists in various clinical 136 
teams (champions) to look after this when they do their normal ward rounds. We 137 
support them and help them with audits but optimal antifungal prescribing is their 138 
responsibility´ 139 
 140 
There were a variety of different reasons for commencing an AFS programme 141 
including: financial concerns (13; 52%), clinical need (12; 48%), attempts to improve 142 
patient management (40%) and interested individuals. Interestingly, only two 143 
respondents suggested concerns about antifungal resistance as a reason for starting 144 
their programme. A variety of resources were used for commencing AFS. The most 145 
frequent resource cited was discussions (with colleagues or experts), teaching 146 
events / meetings, and literature searches. One hospital Trust recruited two medical 147 
mycologists specifically to set up an AFS programme, whilst another AFS 148 
programme resulted from an audit of antifungal prescribing. 149 
 150 
Patients were identified by a variety of different mechanisms. Pharmacy records 151 
were used to detect patients receiving antifungal agents (18), via microbiology 152 
results (13) and queries from clinicians (15). Six respondents performed specialty-153 
specific ward rounds. 154 
 155 
Many centres have an antimicrobial pharmacist (19; across all hospital types), a 156 
microbiologist or Infectious Disease physician, a database and access to TDM. A 157 
small majority of trusts performed TDM (57%). 158 
 159 
Most respondents reported that as part of their AFS programme, they assessed 160 
clinical response (19), highlighted drug-drug interactions (15), addressed side-effects 161 
(14) and ensured appropriate use of TDM / fungal biomarkers (17 each). Other 162 
comments included checking compliance to guidelines / evidence-based use. 163 
Measures used to assess effectiveness included monitoring the likelihood of 164 
obtaining adequate therapeutic drug levels (17), costs of antifungal agents (13), 165 
resistance profile (10) and mortality data (5). Other Trusts obtained surveillance data 166 
as part of their AFS programme0RVWUHVSRQGHQWVWKRXJKWWKHLUDGYLFHZDVµXVXDOO\¶167 
IROORZHGWKRXJKVRPHVXJJHVWHGLWZDVµVRPHWLPHV¶IROORZHG 168 
 169 
The majority (79%) of respondents would ideally perform more AFS duties. One 170 
UHVSRQGHQW UHSRUWHG WKH\¶Gneeded to suspend their AMS service (and hence AFS 171 
service) due to staffing issues. 172 
 173 
A number of reasons were suggested by the 21 respondents who did not perform 174 
AFS. These included lack of time, competing priorities, perceived lack of importance 175 
and lack of expertise. Three respondents suggested that funding by NHS England 176 
for high cost antifungal drugs was a reason for not performing AFS (so any financial 177 
VDYLQJV GLGQ¶W EHQHILW WKH Trust). Other reasons for not performing AFS included 178 
µORZHUQXPEHUV¶µDntifungal use is relatively less¶DQGOack of interest / engagement 179 
from other specialties (e.g. haematology). 180 
 181 
Availability of rapid diagnostics, clinical support (57% each) and more resources 182 
(52%) could help persuade some clinicians to start an AFS service, but CPD events 183 
(43%) and E-learning programmes (29%) were not considered to be beneficial. 184 
 185 
 186 
Discussion 187 
The clinical and financial benefits of AFS are well described (Standiford et al 2012, 188 
Lopez-Medrano 2013, Mondain et al 2013, Valerio et al 2014, Micallef et al 2015). 189 
Most studies up until now have suggested financial benefits as the principal reason 190 
for performing it. However, even small studies targeting the management of patients 191 
with candidaemia have shown improvements in mortality (Gouliouris et al 2016). 192 
There are important differences between AMS and AFS (table 2). Clinicians are less 193 
familiar with fungal infections, in terms of diagnostics and therapy and some drugs 194 
can be toxic and the azole antifungal agents have multiple interactions. Some 195 
antifungals are expensive. Patients with fungal infections (or suspected fungal 196 
infection) also typically have multiple co-morbidities and / or are extremely unwell. 197 
 198 
We provide data on an important and emerging area from a national survey. Most 199 
respondents recognised the potential benefits of an AFS program. Not surprisingly, 200 
most NHS acute Trusts in England responded to say they had an AMS programme 201 
in place. We found that microbiologists and antimicrobial pharmacists are the 202 
clinicians most involved in AFS. However, only 76% of acute Trusts had guidelines 203 
for the treatment and or prophylaxis of fungal infections and only 57% of Trusts 204 
performed TDM on some azoles, despite national guidelines suggesting its 205 
importance (Ashbee et al 2015).  206 
 207 
A variety of methods for performing AFS are described, from dedicated ward rounds 208 
(at least weekly) to ad-hoc arrangements as and when required. This varied 209 
according to institution. Some hospitals perform it as part of their AMS programme 210 
(currently suspended due to lack of resources in at least one hospital) whilst one 211 
hospital had appointed two mycologists to help with AFS. Patients were typically 212 
identified by either laboratory results or pharmacy records in most cases. 213 
 214 
Most Trusts had access to a range of fungal biomarkers, although not necessarily in 215 
their own hospital. However, the turnaround times were typically prolonged (>48 216 
hours), which limits their clinical impact and utility for clinicians. This was highlighted 217 
in comments from several respondents. Fungal diagnostics is an area of difficulty for 218 
many clinicians and hugely important if antifungal agents are to be used 219 
appropriately and there is some evidence from this survey that some clinicians are 220 
unfamiliar and not confident with their interpretation. One laboratory expressed 221 
dissatisfaction in the funding of diagnostic tests (funded for certain patients but not 222 
others).  223 
 224 
Most respondents thought their advice was µXVXDOO\¶ IROORZHG +RZHYHU WKH225 
comments section suggests some areas (e.g. haematology / respiratory medicine) 226 
are less engaged or reluctant to follow advice from an AFS team of microbiologist 227 
and antimicrobial pharmacist. One way, suggested by Manchester, circumvented the 228 
issue by giving ownership back to the clinical team, who ultimately are responsible 229 
for the patient. 230 
 231 
Most respondents who perform AFS would do more if they had the available 232 
resources. One hospital had reduced its AFS programme as a clinician had left and 233 
no-one had replaced them. Standiford reported the situation where costs fell when 234 
an AFS programme was instituted and then rose when it was withdrawn (Standiford 235 
et al).  236 
 237 
The funding mechanism in England is different from other countries in the United 238 
Kingdom. Most systemic antifungals, excluding fluconazole, itraconazole, 239 
ketoconazole and flucytosine are classified as high cost drugs, and are funded 240 
separately outside of the payment by results (PBR) or tariff system  241 
(https://www.england.nhs.uk/resources/pay-syst/drugs-and-devices/high-cost-drugs/) 242 
. Hospitals are required to provide patient level information to receive direct payment 243 
for the antifungals they use.  A national Quality, Innovation, Productivity and 244 
Prevention (QIPP) incentive scheme has slightly reduced consumption on high-cost 245 
antifungals as defined daily doses (DDD), but the use of antifungals with expired or 246 
soon to expire patents (i.e. voriconazole and caspofungin) where cheaper costs will 247 
be seen has actually fallen. Most of the savings seen from the use of generic 248 
voriconazole has funded more expensive antifungals with years to run on their 249 
patents (data from www.RX-info.com). Future NHS England incentive schemes are 250 
IRFXVLQJ RQ SD\LQJ WKH ORZHVW FRVW IRU ³RII-SDWHQW´ DQWLIXQJDOV251 
(https://www.england.nhs.uk/wp-content/uploads/2016/11/ge3-hospital-medicines-252 
optimisation.pdf)), but unless all high cost antifungals are removed from the tariff 253 
exclusion list, there will only be limited improvements in antifungal stewardship. 254 
 255 
Our study, in common with a number of questionnaire studies, has a number of 256 
limitations. The return rate was only 30% which compares to other similar studies 257 
(Burns 2009). Nevertheless, we present data from a range of hospital Trusts of 258 
different types and involving different types of patients. Bias is inherent in any 259 
questionnaire; clinicians with an interest in AFS may have been more likely to 260 
respond than others. 261 
 262 
AFS has been shown to have significant benefits to patients. We suggest that AFS is 263 
being performed in most hospitals in a variety of different ways in England which in 264 
part reflects different patient populations. Most hospitals would do more if they had 265 
the resources to do it, suggesting improvements can still be made. 266 
  267 
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Table 1: Results of Antifungal stewardship questionnaire 357 
1. Background data 
Total number of responses (de-duplicated, excluding 
non-English Trusts) 
54  
Total number of acute Trusts with identified names 47 (30% of English 
Trusts) 
 
Number of Trusts with multiple replies (2 or 3) 6  
Number of Trusts outside England that responded 
(not included in analysis) 
3  
Type of Hospital Trust Total Responding 
Trusts (n = 47) 
% 
District General  25 53 
Teaching  17 36 
Specialist 5 11 
Job Title of Respondents Total Respondents 
(n = 54) 
% 
Microbiologists 37 69 
Antimicrobial Pharmacist 8 15 
Director of Infection Prevention & Control 2 4 
Infectious Diseases Physician 3 6 
Mycologist 1 2 
Others (Clinical Pharmacy Technician, Microbiology 
Manager & Microbiology Registrar) 
3 6 
Specialties provided at the hospital Total Responding 
Trusts (n = 47) 
% 
Burns 10 21 
Haematology-Oncology 40 85 
Infectious Diseases and Immunity 16 34 
Intensive Care Unit (ICU) 45 96 
Paediatric ICU / Neonatal PICU/NICU 36 77 
Respiratory Diseases 45 96 
Cardiology 44 94 
Solid Organ Transplant (State) 13 28 
Stem Cell Transplant: Allograft 12 26 
Stem Cell Transplant: Autograft 17 36 
Care of the Elderly 43 91 
Others: 
 kidney, liver, pancreas, small bowel; renal and  pancreas transplant 
 Neurosurgery 
 Maxillo-facial surgery 
 Ear, Nose & Throat (ENT) surgery 
 Cardiothoracic surgery 
 Cystic fibrosis 
 Bone tumour and bone / joint infection 
 Spinal cord injury rehabilitation 
 Intestinal failure 
Does the Trust have an AMS Programme? Total Responding 
Trusts (n = 47) 
% 
Yes 46 98 
No 1 2 
Does the Trust have a dedicated AFS 
Programme? 
Total Responding 
Trusts (n = 47) 
% 
Yes - we have a dedicated antifungal stewardship 
programme 5 
11 
Sort of - we include antifungal stewardship as part of 
our antimicrobial stewardship programme 20 
43 
Not really, but we do monitor antifungal usage 12 26 
No 9 19 
Benefits of AFS Total Responding 
Trusts (n =47) 
% 
Improved safety 23  
Improved outcome 19  
Save money 24  
Reduced side-effects 20  
Obtain surveillance data to devise antifungal 
treatment guidelines 
18  
Do you have the following fungal guidelines? Trusts Responding 
to Section (n = 36) 
% 
Trusts who had fungal guidelines (either prophylaxis, 
treatment or both) 
25 76 
Do you perform triazole therapeutic drug 
monitoring? 
Trusts Responding 
to Section (n = 46) 
% 
Yes 26 57 
No 17 37 
'RQ¶WNQRZ 3 6 
Available Fungal biomarker tests Trusts Responding 
to section (n = 47)  
% 
Galactomannan 44 94 
Beta-D-glucan 36 77 
PCR: PCP 41 87 
PCR: Candida 22 47 
PCR: Aspergillus 26 55 
PCR: Pan-fungal 31 66 
Mannan Ag/Ab 14 30 
Cryptococcal Ag 43 91 
Fungal biomarker tests 
turnaround times 
<48 hours 48 - 96 hours >96 hours 
Galactomannan 5 17 14 
ȕ-D-glucan 4 15 11 
PCR: PCP 8 16 8 
PCR: Candida 1 8 8 
PCR: Aspergillus 3 8 10 
PCR: Pan-fungal 0 9 16 
Mannan Ag/Ab 0 5 3 
Cryptococcal Ag 19 11 7 
2. In hospitals with an AFS programme in place, 
the majority of AFS ward rounds were performed 
by: 
Trusts Responding 
to Section (n = 25) 
% 
Microbiologist 21 84 
Antimicrobial pharmacist 13 52 
Infectious disease physician 5 25 
ICU pharmacist 2 8 
Haematology pharmacist 1 4 
ICU physician 1 4 
Which of these form part of your AFS 
programme? 
Trusts Responding 
to Section (n = 25) 
% 
Have an AFS / management team  7 28 
Monitor and report on antifungal use  16 64 
Dedicated AFS ward rounds  5 20 
AFS team have direct involvement in management 
of invasive fungal infections (e.g. candidaemia and 
aspergillosis)  12 
48 
How often are AFS ward rounds performed in a 
typical week? 
Trusts Responding 
to Section (n = 25) 
% 
Daily 3  
2 - 3 times per week 1  
Weekly 10  
Fortnightly 0  
Monthly  0  
Why was your AFS programme started? Trusts Responding % 
to Section (n = 25) 
Clinical need  12 48 
Improve antifungal management  10 40 
Manage antifungal costs  13 52 
Manage antifungal resistance  2 8 
Concerns over worsening outcomes of patients with 
fungal infections  3 
12 
Request from clinicians  0 0 
Other, please specify 
 Special interest in clinical mycology 
 :HGRQ¶WKDYHDVHSDUDWH$)6EXWLWLVSDUWRIRXUAMS 
 As part of Antibiotic stewardship Programme 
 Part of antimicrobial stewardship rounds 
 Current antimicrobial stewardship started Aug 2014-no dedicated AFS programme; 
but as (relatively small) part of general antimicrobial stewardship 
 Started as an audit and re-audit 
What resources did you use to develop your AFS 
programme? 
Trusts Responding 
to Section (n = 25) 
% 
CPD event  6 24 
Discussions with colleagues 14 56 
Discussions with experts 6 24 
Literature search 11 44 
Peer meetings where AFS has been tried and tested 7 28 
Not known 3 12 
Other, please specify: 
x Recruitment of 2 medical mycologists to set up AFS 
x In house audit of AF prescribing 
x Involvement with the ESCMID antifungal guideline writing groups 
How do you target patients?  Trusts Responding 
to Section (n = 25) 
% 
Drug prescriptions (pharmacy records) 18 72 
Laboratory results / organisms 13 52 
Queries from clinicians 15 60 
Specialty  6 24 
What resources do you have available? Trusts Responding 
to Section (n 25) 
% 
IT database for collecting data 9 36 
Therapeutic drug monitoring 17 68 
Antimicrobial pharmacist 20 80 
Dedicated microbiologist 11 44 
Infectious disease physician 5 20 
Other: 
x Electronic prescribing - we can see who is on antifungals 
x Unsure about adults. Paediatrics have a motivated oncologist 
x The Microbiologist is often involved in starting antifungals 
How do you monitor therapy? Trusts Responding 
to Section (n = 25) 
% 
Efficacy (i.e. clinical response) 19 76 
Highlighting drug-drug interactions 15 60 
Highlighting/preventing side-effects 14 56 
Appropriate use of therapeutic drug monitoring  17 68 
Appropriate use of fungal biomarkers 17 68 
Other 
x Compliance to guidelines/evidence-based use 
x Compliance with antimicrobial prescribing guidelines 
x Confirming diagnosis 
How do you monitor effectiveness? Trusts Responding 
to Section (n = 25) 
% 
Efficacy (i.e. clinical response) 21 84 
Clinical parameters (e.g. respiratory function, 
normalisation of inflammatory markers, imaging etc.) 
18 72 
Highlighting / preventing side effects 15 60 
Obtaining adequate therapeutic drug levels 17 68 
Highlighting and reducing drug-drug interactions 18 72 
Cost of antifungal drug budget  13 52 
Resistance profile 10 40 
Mortality data 5 25 
Other 
x Surveillance of candidaemia and other serious fungal diseases 
Do you provide advice? Trusts Responding 
to Section (n = 25) 
% 
Yes: Verbal advice 21 84 
Yes: Written advice 16 64 
No 0 0 
Do clinicians follow your advice? Trusts Responding 
to Section (n = 25) 
% 
Always 2 8 
Usually 16 64 
Sometimes 4 16 
Rarely 0 0 
Never 0 0 
Don't know 0 0 
Would you do more AFS if you could? Trusts Responding 
to Section (n = 34) 
% 
Yes 27 79 
No 4 12 
'RQ¶WNQRZ 3 9 
3. Please specify the reasons for not performing 
AFS 
Trusts Responding 
to Section (n = 21) 
% 
Competing priorities 10 48 
Funding by NHS England for high cost antifungal 
drugs 3 
14 
Lack of interest 2 10 
Lack of resources: staff time 14 67 
Lack of resources: expertise 3 14 
Perceived lack of importance 5 24 
Other, please specify 
x Antifungal use is relatively less 
x Lower numbers 
x Lack of interest from haematology side 
If these barriers were addressed, would you do 
AFS? 
Trusts Responding 
to Section (n = 18) 
% 
Yes 16 89 
No 2 11 
What would convince you to do AFS? Trusts Responding 
to Section (n = 21) 
% 
Availability of rapid diagnostics (i.e. within 48h) 12 57 
Clinical support 12 57 
CPD Events 9 43 
E-learning programmes 6 29 
More resources 11 52 
Comments 
³Huge impact on appropriate prescribing by implementing a systemic antifungal guideline´ 
³Rapid in house testing for candida isolates so we can de-escalate to azoles quickly´ 
³Rapid availability of HRCT´ 
³We used to do weekly antifungal WR's which were excellent. We haven't resumed these 
since a colleague left and none of the other microbiologists have the expertise.´ 
³We also struggle to fit everything in, so lack of time is a major factor. Also the fact that 
other things have become more 'important'...e.g. CQUIN for antibiotic reduction so time and 
effort are currently being directed elsewhere´. 
³Antifungals are also hugely complicated so training would be greatly received......´ 
³Anti-fungal stewardship is challenging in transplant and respiratory patients: the transplant 
team is usually set in their ways as to how they manage their patients and also fear of 
clinical failure if antifungals are stopped´. 
³The respiratory team (bronchiectasis and CF) usually rely on radiology findings rather than 
on biomarkers.´ 
³Although GM is available the TAT is not satisfactory for stewardship´ 
³We have problems with funding of this test´ 
³The Trust does not invest enough in pharmacy/microbiology´ 
³The number of prescriptions for antifungals in the trust is very small´ 
³There is little or no microbiological oversight of antifungal use in haematology-oncology or 
respiratory, otherwise most antifungals are used on the basis of advice from a consultant 
microbiologist´ 
³The Wythenshawe antifungal stewardship (AFS) team consists of two members of the 
Infectious Diseases (ID) team (a Consultant Medical Mycologist & a Consultant in ID) and 
an antimicrobial Pharmacist in addition to a group of Champions and it is led by ID.´ 
³The key targets of the programme are to improve patient outcomes by updating and 
clarifying antifungal guidelines, involving and educating champions, implementing better 
GLDJQRVWLFVȕ-D-glucan, therapeutic drug monitoring, resistance monitoring) and by 
stopping unnecessary courses of antifungals.´ 
³Mortality to fungal infections, antifungal resistance and cost of IV antifungals were chosen 
as outcome measures. The UHSM AFS programme has been successful in decreasing 
mortality to candidaemia, in stopping the increase of azole resistance in Aspergillus 
fumigatus and in decreasing the cost of echinocandins antifungal drugs used.´ 
³By integrating AFS into the team members' job plans this has achieved minimal additional 
staff costs. Savings in antifungal consumption has covered the increase in diagnostic costs.´ 
³Staff engagement has been one of the areas where we believe we have had the most 
success, and is showing the programme to be sustainable.´ 
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Table 2: Comparison between antimicrobial stewardship (AMS) versus antifungal 360 
stewardship (AFS) 361 
 
Antimicrobial stewardship Antifungal stewardship 
 
Source of infection Patient to patient 
transmission 
Patient to patient 
transmission is rare but can 
occur by endogenous 
infection with some fungi. 
Infection is often acquired 
from the environment e.g. via 
inhalation, inhalation, 
SDWLHQW¶VRZQIORUDRUGHYLFHV
such as catheters 
Clinical data A lot of supporting clinical 
data 
Relative lack of clinical data 
Toxicity and drug-drug 
interactions 
Less common More common 
Diagnostic and monitoring 
tests 
More tools available for 
interpretation 
Fewer tools available that 
can also be difficult to 
interpret 
Therapeutic drug 
monitoring 
Therapeutic drug monitoring 
regularly used 
Therapeutic drug monitoring 
developing 
Staff familiarity Greater familiarity Less confidence and 
familiarity 
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